Characteristics of Islet β-cell Functions in Chinese Patients With Graves' Disease

Weikai Hou

Status: Completed

Conditions: Graves Disease

Treatments: Drug: Methimazole

Study type: Observational

Funder types: Other

Identifiers

NCT02376088

GD-003

Details and patient eligibility

About

Patients with GD often present with glucose dysregulation, which, according to most studies, is associated with islet β-cell dysfunctions, enhanced gluconeogenesis and insulin resistance (IR). Current studies focus mainly on IR, and a few that investigate islet β-cell functions show inconsistent results. This study examined the characteristics of glucose dysregulation in Chinese patients with GD, and furthermore evaluated the effects of thyroid dysfunction on islet β-cell functions and subsequently the carbohydrate metabolism.

Full description

Thyroid dysfunction is closely associated with glucoregulation. Carbohydrate metabolism can be affected with decreased levels of thyroid hormone (TH), even more so with an elevated TH level. Epidemiological data shows that 2%-57% of patients with Graves' Disease (GD) present with glucose dysregulation, which might also be related to the changes in islet β-cell functions in patients with GD. The incidence of GD has comparable variations geographically, with possibly different underlying mechanisms, such as an excessive intake of iodine resulting in an aggravation of autoimmune reactions from thyroid and consequently an increment in incidence of GD. The same might also be true in glucoregulation and islet β-cell functions in patients with GD. This study aims to examine the characteristics of glucoregulation and islet β-cell functions in patients with GD in different areas of China, using early-phase insulin secretion index (△I30/△G30), glucose area under curve(GAUC) and insulin area under curve(INSAUC).

Enrollment: 328 patients

Sex: All

Ages: 18 to 75 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Patients with Graves Disease
• Age-matched healthy checkup subjects

Exclusion criteria

• Patients with a medical history of diabetes, pancreatitis and other related conditions and positive family histories as well as medication history of glucocorticoid and anti-diabetic agents

Trial design

328 participants in 7 patient groups

GA1

Description:

subjects from coastal areas who initiated Methimazole treatment for the first time on enrollment

Treatment:

Drug: Methimazole

GA2

Description:

subjects from coastal areas who were under Methimazole treatment and with an elevated TH level

Treatment:

Drug: Methimazole

GA3

Description:

subjects from coastal areas who were under Methimazole treatment and with a normal TH level

Treatment:

Drug: Methimazole

GB1

Description:

subjects from non-coastal areas who initiated Methimazole treatment for the first time on enrollment

Treatment:

Drug: Methimazole

GB2

Description:

subjects from non-coastal areas who were under Methimazole treatment and with an elevated TH level

Treatment:

Drug: Methimazole

GB3

Description:

subjects from non-coastal areas who were under Methimazole treatment and with a normal TH level

Treatment:

Drug: Methimazole

NC

Description:

age-matched healthy checkup subjects